# Blood (HS4 3002) Trade Overview | Yugalinks

> Published by **Yugalinks**, global trade intelligence for growing businesses.
>
> [Follow Yugalinks on LinkedIn](https://in.linkedin.com/company/yugalinks)

Blood at HS4 3002, with reported global trade through 2024.

Canonical: https://www.yugalinks.com/trade/sector/hs4/3002

## Explore Yugalinks

- [Open the trade workspace](https://www.yugalinks.com/app)
- [Read the methodology](https://www.yugalinks.com/methodology)
- [Review data sources](https://www.yugalinks.com/data-sources)
- [Check data coverage](https://www.yugalinks.com/data-coverage)
- [Read Responsible AI principles](https://www.yugalinks.com/responsible-ai)

## Answer

The blood subsector recorded $360.9B in reported global trade in 2024, with +1.5% annual change.

## Key figures

| Measure | Value |
| --- | --- |
| Latest reported trade | $360.9B |
| Latest annual change | +1.5% |
| Active exporters | 191 |
| Active importers | 200 |
| Active HS6 products | 8 |

## Annual trend

| Year | Global trade | Corridors | HS6 products |
| --- | ---: | ---: | ---: |
| 1995 | $5.5B | 3,511 | 4 |
| 1996 | $6.1B | 3,492 | 4 |
| 1997 | $6.7B | 3,501 | 4 |
| 1998 | $6.7B | 3,494 | 4 |
| 1999 | $9.2B | 3,890 | 4 |
| 2000 | $10.4B | 4,530 | 4 |
| 2001 | $12.5B | 4,646 | 4 |
| 2002 | $15.3B | 4,757 | 4 |
| 2003 | $20.7B | 4,944 | 4 |
| 2004 | $26.9B | 5,121 | 4 |
| 2005 | $29.8B | 5,250 | 4 |
| 2006 | $37.1B | 5,309 | 4 |
| 2007 | $51.8B | 5,578 | 4 |
| 2008 | $65.4B | 5,769 | 4 |
| 2009 | $75.2B | 5,946 | 4 |
| 2010 | $83.0B | 6,207 | 4 |
| 2011 | $91.7B | 6,413 | 4 |
| 2012 | $98.7B | 6,620 | 9 |
| 2013 | $108.8B | 6,801 | 9 |
| 2014 | $121.3B | 6,875 | 9 |
| 2015 | $119.6B | 6,991 | 9 |
| 2016 | $131.9B | 7,133 | 9 |
| 2017 | $158.1B | 7,243 | 9 |
| 2018 | $184.7B | 7,426 | 9 |
| 2019 | $202.5B | 7,611 | 9 |
| 2020 | $232.6B | 7,600 | 9 |
| 2021 | $351.6B | 8,237 | 9 |
| 2022 | $328.8B | 8,610 | 8 |
| 2023 | $328.0B | 8,394 | 8 |
| 2024 | $360.9B | 8,364 | 8 |

## Leading corridors

- Ireland to USA, Puerto Rico and US Virgin Islands: $30.1B; growth +12.1%.
- Switzerland, Liechtenstein to USA, Puerto Rico and US Virgin Islands: $14.6B; growth +10.7%.
- Germany to USA, Puerto Rico and US Virgin Islands: $13.9B; growth +9.3%.
- Singapore to USA, Puerto Rico and US Virgin Islands: $9.2B; growth +50.8%.
- Belgium to USA, Puerto Rico and US Virgin Islands: $9.0B; growth +9.4%.
- Ireland to Netherlands: $7.6B; growth +105.3%.
- Switzerland, Liechtenstein to Germany: $7.5B; growth +5.3%.
- USA, Puerto Rico and US Virgin Islands to Germany: $7.2B; growth +14.2%.
- Ireland to Belgium: $5.5B; growth -23.4%.
- USA, Puerto Rico and US Virgin Islands to Japan: $4.2B; growth +7.8%.

## HS6 products

- Blood: human or animal, antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes (HS6 300210)
- Blood, human or animal, antisera, other blood fractions and immunological products: malaria diagnostic test kits (HS6 300211)
- Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions (HS6 300212)
- Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale (HS6 300213)
- Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale (HS6 300214)
- Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale (HS6 300215)
- Blood, human or animal, antisera, other blood fractions and immunological products: n.e.c. in heading 3002.1 (HS6 300219)
- Vaccines: for human medicine (HS6 300220)
- Vaccines: for veterinary medicine (HS6 300230)
- Vaccines: for veterinary medicine, against foot and mouth disease (HS6 300231)
- Vaccines: for veterinary medicine, for other uses than against foot and mouth disease (HS6 300239)
- Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: for human medicine (HS6 300241)
- Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: for veterinary medicine (HS6 300242)
- Toxins, cultures of micro-organisms (excluding yeasts) and similar products: n.e.c. in item 3002.3 (HS6 300249)
- Cell cultures, whether or not modified: cell therapy products (HS6 300251)
- Cell cultures, whether or not modified: other cell cultures not including cell therapy products (HS6 300259)
- Toxins, cultures of micro-organisms (excluding yeasts) and similar products (HS6 300290)

## Definitions and coverage

Merchandise trade observations aggregated to HS4. Growth, concentration, volatility, and peak comparisons calculated from reported observations. Missing values remain unavailable and are not imputed.

Reported observations cover 1995-2024.

## Continue your research

- [Explore HS4 3002 in the workspace](https://www.yugalinks.com/app?hs=3002)
- [Open the Yugalinks workspace](https://www.yugalinks.com/app)

## Other formats

- [HTML](https://www.yugalinks.com/trade/sector/hs4/3002/index.html)
- [JSON](https://www.yugalinks.com/trade/sector/hs4/3002/index.json)
- [JSON-LD](https://www.yugalinks.com/trade/sector/hs4/3002/index.ld.json)


## Continue your research

- [Explore HS4 3002 in the workspace](https://www.yugalinks.com/app?hs=3002)
- [Open the Yugalinks workspace](https://www.yugalinks.com/app)

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-27). [OECD Data Explorer](https://data-explorer.oecd.org/) · [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) · [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) · [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.